Axitinib, a new therapeutic option in renal cell carcinoma

Drugs of Today

Volumn 48, Issue 10, 2012, Pages 633-644

  Kessler, E R ^a   Bowles, D W ^a,b   Flaig, T W ^a   Lam, E T ^a   Jimeno, Antonio ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Axitinib; Platelet derived growth factor receptor; Proto oncogene c Kit; Renal cell carcinoma; VHL gene

Indexed keywords

ATAZANAVIR; AXITINIB; BEVACIZUMAB; CARBAMAZEPINE; CLARITHROMYCIN; DEXAMETHASONE; EVEROLIMUS; INDINAVIR; INTERFERON; ITRACONAZOLE; KETOCONAZOLE; NEFAZODONE; NELFINAVIR; PAZOPANIB; PHENOBARBITAL; PHENYTOIN; PLACEBO; RIFAMPICIN; RITONAVIR; SAQUINAVIR; SORAFENIB; STEM CELL FACTOR; SUNITINIB; TELITHROMYCIN; TEMSIROLIMUS; VASCULOTROPIN; VORICONAZOLE;

AREA UNDER THE CURVE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; KIDNEY CARCINOMA; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 84869225508     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.10.1860768     Document Type: Review

References (77)

1. Janzen, N.K., Kim, H.L., Figlin, R.A., Belldegrun, A.S. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003, 30(4): 843-52. (Pubitemid 37485197)
2. Rini, B.I., Atkins, M.B. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009, 10(10): 992-1000.
3. Kaelin, W.G., Jr. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 2009, 115(10, Suppl.): 2262-72.
4. Jubb, A.M., Pham, T.Q., Hanby, A.M. et al. Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol 2004, 57(5): 504-12. (Pubitemid 38621796)
5. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3(10): 721-32. (Pubitemid 37328811)
6. Fabian, M.A., Biggs, W.H., 3rd, Treiber, D.K. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005, 23(3): 329-36. (Pubitemid 41094421)
7. Gerlinger, M., Rowan, A.J., Horswell, S. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366(10): 883-92.
8. Escudier, B., Porta, C., Bono, P. et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)-PISCES study, NCT 01064310. J Clin Oncol [48th Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2012] 2012, 30(Suppl.): Abst CRA4502.
9. Carmeliet, P., Jain, R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011, 10(6): 417-27.
10. Carmeliet, P., Jain, R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473(7347): 298- 307.
11. De Bock, K., Mazzone, M., Carmeliet, P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 2011, 8(7): 393-404.
12. Carmeliet, P., Jain, R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407(6801): 249-57.
13. Laramee, M., Chabot, C., Cloutier, M., Stenne, R., Holgado- Madruga, M., Wong, A.J., Royal, I. The scaffolding adapter Gab1 mediates vascular endothelial growth factor signaling and is required for endothelial cell migration and capillary formation. J Biol Chem 2007, 282(11): 7758-69. (Pubitemid 47093597)
14. Gerber, H.P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B.A., Dixit, V., Ferrara, N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998, 273(46): 30336- 43.
15. Takahashi, T., Yamaguchi, S., Chida, K., Shibuya, M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGFA- dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 2001, 20(11): 2768-78. (Pubitemid 32938560)
16. Lamalice, L., Houle, F., Jourdan, G., Huot, J. Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene 2004, 23(2): 434-45. (Pubitemid 38174998)
17. Lennartsson, J., Ronnstrand, L. The stem cell factor receptor/c-Kit as a drug target in cancer. Curr Cancer Drug Targets 2006, 6(1): 65-75.
18. Heinrich, M.C., Blanke, C.D., Druker, B.J., Corless, C.L. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002, 20(6): 1692-703. (Pubitemid 34260552)
19. Huo, L., Sugimura, J., Tretiakova, M.S. et al. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum Pathol 2005, 36(3): 262-8. (Pubitemid 40404009)
20. Rugo, H.S., Herbst, R.S., Liu, G. et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005, 23(24): 5474-83.
21. Duignan, I.J., Corcoran, E., Pennello, A. et al. Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models. Neoplasia 2011, 13(1): 49-59.
22. Sonpavde, G., Hutson, T.E., Rini, B.I. Axitinib for renal cell carcinoma. Expert Opin Investig Drugs 2008, 17(5): 741-8. (Pubitemid 351843617)
23. Hu-Lowe, D.D., Zou, H.Y., Grazzini, M.L. et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG- 013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008, 14(22): 7272-83.
24. Inai, T., Mancuso, M., Hashizume, H. et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004, 165(1): 35-52. (Pubitemid 38821812)
25. Pfizer Global Research and Development. AG-013736: Investigator's Brochure. Pfizer Global Research and Development, La Jolla, CA, 2004.
26. Rini, B.I., Schiller, J.H., Fruehauf, J.P. et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011, 17(11): 3841-9.
27. Mancuso, M.R., Davis, R., Norberg, S.M. et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006, 116(10): 2610-21. (Pubitemid 44511625)
28. Pfizer Inc. Inlyta (Axitinib). Full prescribing information. January 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/202324lbl.pdf. Accessed September 10, 2012.
29. Pithavala, Y.K., Tortorici, M., Toh, M. et al. Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol 2010, 65(3): 563-70.
30. Hoskins, J.M., Goldberg, R.M., Qu, P., Ibrahim, J.G., McLeod, H.L. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007, 99(17): 1290-5. (Pubitemid 47394168)
31. Liu, G., Rugo, H.S., Wilding, G. et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005, 23(24): 5464-73.
32. Yuh, W.T. An exciting and challenging role for the advanced contrast MR imaging. J Magn Reson Imaging 1999, 10(3): 221-2. (Pubitemid 29463103)
33. Li, K.L., Wilmes, L.J., Henry, R.G. et al. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. J Magn Reson Imaging 2005, 22(4): 511-9. (Pubitemid 41416410)
34. Wilmes, L.J., Hylton, N.M., Wang, D.H. AG-013736, a novel VGFR TK inhibitor, suppresses tumor growth and vascular permeability in human BT474 breast cancer xenografts in nude mice. Proc Am Assoc Cancer Res [94th Annu Meet Am Assoc Cancer Res (AACR) (July 10-14, Washington, D.C.) 2003] 2003, 44: Abst 3772.
35. Rini, B., Rixe, O., Bukowski, R. et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates antitumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol [41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005] 2005, 23: Abst 4509.
36. Rixe, O., Bukowski, R.M., Michaelson, M.D. et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007, 8(11): 975-84. (Pubitemid 47629888)
37. Rini, B.I., Wilding, G., Hudes, G. et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009, 27(27): 4462-8.
38. Flaig, T.W., Kim, F.J., La Rosa, F.G., Breaker, K., Schoen, J., Russ, P.D. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs 2009, 27(1): 83-7.
39. Tomita, Y., Uemura, H., Fujimoto, H. et al. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. Eur J Cancer 2011, 47(17): 2592-602.
40. Uemura, H., Shinohara, N., Yuasa, T. et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 2010, 40(3): 194-202.
41. Yoo, C., Kim, J.E., Lee, J.L. et al. The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 2010, 40(10): 980-5.
42. Zhang, H., Dong, B., Lu, J.J. et al. Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study. BMC Cancer 2009, 9: 249.
43. Trask, P.C., Bushmakin, A.G., Cappelleri, J.C., Bycott, P., Liau, K., Kim, S. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib. Acta Oncol 2008, 47(5): 843-51. (Pubitemid 351882727)
44. Heinzer, H., Mir, T.S., Huland, E., Huland, H. Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J Clin Oncol 1999, 17(11): 3612-20. (Pubitemid 29517934)
45. Yang, S., de Souza, P., Alemao, E., Purvis, J. Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. Br J Cancer 2010, 102(10): 1456-60.
46. Cella, D., Li, J.Z., Cappelleri, J.C. et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol 2008, 26(22): 3763-9.
47. Rini, B.I., Escudier, B., Tomczak, P. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378(9807): 1931-9.
48. Michaelson, M.D., Rini, B., Escudier, B. et al. Phase III AXIS trial of axitinib versus sorafenib in metastatic renal cell carcinoma: Updated results among cytokine-treated patients. J Clin Oncol [48th Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2012] 2012, 30(Suppl.): Abst 4546.
49. Rini, B.I., Tamaskar, I., Shaheen, P. et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007, 99(1): 81-3.
50. Tamaskar, I., Bukowski, R., Elson, P. et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 2008, 19(2): 265-8. (Pubitemid 351201706)
51. Mukohara, T., Nakajima, H., Mukai, H. et al. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci 2010, 101(4): 963-8.
52. Phase III sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH-II) (NCT01613846). ClinicalTrials.gov Web site, Accessed September 20, 2012.
53. Sequential two-agent assessment in renal cell carcinoma therapy (NCT01217931). ClinicalTrials.gov Web site, Accessed September 20, 2012.
54. Temsirolimus versus sorafenib as second-line therapy in patients with advanced RCC who have failed first-line sunitinib (NCT00474786). ClinicalTrials.gov Web site, Accessed September 20, 2012.
55. Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma (NCT00903175). ClinicalTrials.gov Web site, Accessed September 20, 2012.
56. Motzer, R.J., Escudier, B., Oudard, S. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010, 116(18): 4256-65.
57. Rini, B., Grunwald, V., Fishman, M.N. et al. Axitinib for firstline metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study. J Clin Oncol [48th Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2012] 2012, 30(Suppl.): Abst 4503.
58. Neoadjuvant axitinib in locally advanced renal cell carcinoma (RCC) (NCT01263769). ClinicalTrials.gov Web site, Accessed September 20, 2012.
59. Trial of AG-013736, cisplatin, and gemcitabine for patients with squamous non-small cell lung cancer (NCT00735904). ClinicalTrials.gov Web site, Accessed September 20, 2012.
60. AG-013736 in combination with gemcitabine versus gemcitabine alone for patients with metastatic pancreatic cancer (NCT00219557). ClinicalTrials.gov Web site, Accessed September 20, 2012.
61. Adjuvant axitinib therapy of renal cell cancer in high risk patients (NCT01599754). ClinicalTrials.gov Web site, Accessed September 20, 2012.
62. Mendel, D.B., Laird, A.D., Xin, X. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9(1): 327-37. (Pubitemid 36109749)
63. Wilhelm, S.M., Carter, C., Tang, L. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19): 7099-109. (Pubitemid 39331023)
64. Kumar, R., Knick, V.B., Rudolph, S.K. et al. Pharmacokinetic- pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007, 6(7): 2012-21. (Pubitemid 47052491)
65. Escudier, B., Bellmunt, J., Negrier, S. et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010, 28(13): 2144-50.
66. Rini, B.I., Halabi, S., Rosenberg, J.E. et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26(33): 5422-8.
67. Escudier, B., Eisen, T., Stadler, W.M. et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27(20): 3312-8.
68. Motzer, R.J., Hutson, T.E., Tomczak, P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356(2): 115-24. (Pubitemid 46089672)
69. Sternberg, C.N., Davis, I.D., Mardiak, J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28(6): 1061-8.
70. Hudes, G.R., Berkenblit, A., Feingold, J., Atkins, M.B., Rini, B.I., Dutcher, J. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol 2009, 36(Suppl. 3): S26-36.
71. BMS-936558 (MDX-1106) in subjects with advanced/metastatic clear-cell renal cell carcinoma (RCC) (NCT01354431). ClinicalTrials.gov Web site, Accessed September 20, 2012.
72. Motzer, R.J., Nosov, D., Eisen, T. et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. J Clin Oncol [48th Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2012] 2012, 30(Suppl.): Abst 4501.
73. A study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (NCT01030783). ClinicalTrials.gov Web site, Accessed September 20, 2012.
74. An extension treatment protocol for subjects who have participated in a phase 3 study of tivozanib versus sorafenib in renal cell carcinoma (Protocol AV-951-09-301) (NCT01076010). ClinicalTrials.gov Web site, Accessed September 20, 2012.
75. Study of dovitinib versus sorafenib in patients with metastatic renal cell carcinoma (NCT01223027). ClinicalTrials.gov Web site, Accessed September 20, 2012.
76. MK2206 or everolimus in treating patients with refractory kidney cancer (NCT01239342). ClinicalTrials.gov Web site, Accessed September 20, 2012.
77. IMA901 in patients receiving sunitinib for advanced/metastatic renal cell carcinoma (NCT01265901). ClinicalTrials.gov Web site, Accessed September 20, 2012.